We believe that CCL21 administration directionally attracts more mature DCs and naive T cells to the tumor site, ip injection of anti-CD25 mAbs both targets the suppressive activity of Tregs and reduces any risks of developing a systemic neutralizing antibody response [47]. Here, CCL21 is linked to neoplasm.